نتائج البحث - Colleen Burns

  • يعرض 1 - 7 نتائج من 7
تنقيح النتائج
  1. 1
    Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

    Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity حسب Steven R. Smith, Louis J. Aronne, Colleen Burns, Nicole C. Kesty, Amy E. Halseth, Christian Weyer

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

    Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials حسب Ralph A. DeFronzo, John B. Buse, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

    Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabete... حسب Priscilla Hollander, Alok Gupta, Raymond A Plodkowski, Frank L. Greenway, Harold Bays, Colleen Burns, Preston Klassen, Ken Fujioka

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

    The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies حسب John B. Buse, Ralph A. DeFronzo, Julio Rosenstock, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

    A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II) حسب Caroline M. Apovian, Louis J. Aronne, Domenica Rubino, Christopher D. Still, Holly R. Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

    Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes حسب Ian Chapman, Barbara A. Parker, S. Doran, Christine Feinle‐Bisset, Jocelyn Wishart, S. Strobel, Y. Wang, Colleen Burns, Cameron W. Lush, C. Weyer, Michael Horowitz

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

    Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study حسب Louis J. Aronne, Ken Fujioka, Vanita R. Aroda, Kim Chen, Amy E. Halseth, Nicole C. Kesty, Colleen Burns, Cameron W. Lush, Christian Weyer

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: